• Overview
  • Eligibility
  • More info
  • Locations

Cell Kinetic Study of Bromodeoxyuridine (BrdU) in Prostate Cancer (NCT00003832)

Phase II trial to study the effectiveness of broxuridine in treating patients who are undergoing surgery for stage I or stage II prostate cancer. Broxuridine may help doctors determine the rate of growth of prostate tumors and help them plan effective treatment
  • Drug: bromodeoxyuridine
    Given IV
    • 5-BrdU
    • 5-bromodeoxyuridine
    • BrdU
    • broxuridine
  • Procedure: conventional surgery
    Undergo surgery
    • surgery, conventional
  • Other: laboratory biomarker analysis
    Correlative studies
    Ages eligible for Study
    all
    Genders eligible for Study
    Male
    Accepts Healthy Volunteers
    No
    OBJECTIVES:

    I. Measure the potential doubling times of multifocal adenocarcinomas of the prostate using broxuridine.

    II. Determine whether the doubling times of multifocal carcinomas occurring within a single prostate are consistent with a model in which low-volume carcinomas have slow doubling times and high-volume carcinomas have fast doubling times.

    OUTLINE:

    Patients receive broxuridine IV over 30 minutes on day -1. Approximately 12-96 hours later, patients undergo surgery to remove the prostate. Tumor tissue is examined by immunostaining for the presence of broxuridine to determine doubling times of the tumor.

    1 locations

    United States (1)
    • University of Colorado
      Denver, Colorado, United States, 80217-3364
    Status:
    completed
    Type:
    Interventional
    Phase:
    Start:
    30 June, 1999
    Updated:
    23 January, 2013
    Participants:
    75
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!